Silymarin ameliorates Metabolic Risk Factors and Protects against Cardiac Apoptosis in Streptozotocin-induced Diabetic Rats

Monera A Alabdan^1,

¹Biology Department, Princess Nora University, Riyadh, Saudi Arabia

Cite this paper:
Monera A Alabdan. Silymarin ameliorates Metabolic Risk Factors and Protects against Cardiac Apoptosis in Streptozotocin-induced Diabetic Rats. Biomedicine and Biotechnology. 2015; 3(2):20-27. doi: 10.12691/bb-3-2-1

Abstract

The effect of silymarin (SMN) in reducing metabolic risk factors and amelioration of cardiac apoptosis in an experimental model of diabetes was investigated. Streptozotocin (STZ) was injected into male rats (50 mg/kg, ip), and after diabetic induction SMN (80mg/kg) was orally administered for 21 days. Diabetic rats showed a significant decrease in insulin level, hyperglycemia, elevated HOMA-IR, glycosylated hemoglobin (HBA1c), and lipid profile. A significant increase in the lipid peroxidation product malondialdehyde (MDA) and a decrease in the glutathione (GSH) concentration were demonstrated in the heart of the diabetic rats. A significant increase in the activities of creatin kinase-MB (CK-MB) and lactate dehydrogenase (LDH), aspartate amino transferase (GOT), alanine amino transferase (GPT) in the serum of the diabetic rats were demonstrated. Increased numbers of apoptotic cells with down-regulation of Bcl-2 and activation of Bax as well as the caspases-9 and 3 were demonstrated in the diabetic rats. SMN treatment of the diabetic rats ameliorated hyperglycemia, HBA1c, increased insulin secretion, improved HOMA-IR and lipid profile. SMN significantly increased serum HDL. SMN also blunted the increase in MDA and stimulated the GSH production in the heart of STZ-treated rats and improvedredox state. SMN enhanced Bcl-2 expression, blocked the increase of Baxand the caspases 9 and 3. This study demonstrates the effectiveness of SMN in ameliorating myocardial injury in experimental diabetes. This may be related to its antioxidative and anti-apoptotic properties and can be used as antidiabetic complement in case of diabetes mellitus to avoid cardiac complications.

Keywords:
antioxidants apoptosis oxidative stress glutathione

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Figures

References:

[1]	Rolo, A.P. and Palmeira, C.M. (2006). Diabetes and mitochondrial function: role of hyperglycemia and oxidative stress. Toxicol. Appl.Pharmacol. 212(2):167-178.
[2]	Bojunga, J., Nowak, D., Mitrou, P.S., Hoelzer, D., Zeuzem, S.and Chow, K.U.(2004). Antioxidative treatment prevents activation of death-receptor- and mitochondrion-dependent apoptosis in the hearts of diabetic rats. Diabetologia.47(12):2072-2020.
[3]	Dominic, E.A., Ramezani.A., Anker, S.D., Verma, M. Mehta, N. and Rao, M. (2014).Mitochondrial cytopathies and cardiovascular disease.Heart.100(8):611-618.
[4]	Ong, S.B. andHausenloy, D.J. (2010). Mitochondrial morphology and cardiovascular disease.Cardiovasc.Res. 88(1):16-29.
[5]	Ray, S.D., Patel, N., Shah N, Nagori, A. Naqvi, A. and Stohs, S. J. (2006). Pre-exposure to a novel nutritional mixture containing a series of phytochemicals prevents acetaminophen-induced programmed and unprogrammed cell deaths by enhancing BCL-XL expression and minimizing oxidative stress in the liver. Mol. Cell Biochem. 293(1-2):119-136.
[6]	Schinzel, A., Kaufmann, T.and Borner, C. (2004). Bcl-2 family members: integrators of survival and death signals in physiology and pathology [corrected]. Biochim.Biophys.Acta.1644(2-3):95-105.
[7]	Amin, A.H., El-Missiry, M.A. andandOthman, A.I. (2014). Melatonin ameliorates metabolic risk factors, modulates apoptotic proteins, and protects the rat heart against diabetes-induced apoptosis. Eur. J. Pharmacol. 747C:166-173.
[8]	Saravanan, G., Ponmurugan, P., Sathiyavathi, M., Vadivukkarasi, S. and Sengottuvelu, S. (2013). Cardioprotective activity of Amaranthusviridis Linn: effect on serum marker enzymes, cardiac troponin and antioxidant system in experimental myocardial infarcted rats.Int. J. Cardiol. 165(3):494-498.
[9]	El-Abhar, H.S.and Schaalan, M.F. (2014). Phytotherapy in diabetes: Review on potential mechanistic perspectives. World Journal of Diabetes.5(2):176-197..
[10]	Pepping, J. (1999). Milk thistle: Silybummarianum. Am. J. Health. Syst. Pharm. 56(12):1195-1197.
[11]	Matsuda, T.,Ferreri. K., Todorov, I., Kuroda, Y., Smith, C. V., Kandeel, F.and Mullen, Y. (2005). Silymarin protects pancreatic beta-cells against cytokine-mediated toxicity: implication of c-Jun NH2-terminal kinase and janus kinase/signal transducer and activator of transcription pathways. Endocrinology.2005; 146: 175-85.
[12]	Soto, C., Recoba, R., Barron, H., Alvarez, C. and Favari, L. (2003). Silymarin increases antioxidant enzymes in alloxan-induced diabetes in rat pancreas. Comp Biochem. Physiol. C Toxicol.Pharmacol .136: 205-12.
[13]	Li, C.C., Hsiang, C.Y., Wu, S.L.and Ho, T.Y. (2012). Identification of novel mechanisms of silymarin on the carbon tetrachloride-induced liver fibrosis in mice by nuclear factor-kappaB bioluminescent imaging-guided transcriptomic analysis.Food Chem.Toxicol. 50(5):1568-1575.
[14]	Polyak, S. J., Morishima, C., Shuhart, M. C., Wang, C. C., Liu, Y. and Lee, D. Y. ( 2007). Inhibition of T-cell inflammatory cytokines, hepatocyte NF-kappaB signaling, and HCV infection by standardized Silymarin. Gastroenterology. 2007;132(5):1925-1936.
[15]	Shaker, E., Mahmoud, H.and Mnaa, S. (2010). Silymarin, the antioxidant component and Silybummarianum extracts prevent liver damage. Food Chem.Toxicol.48(3):803-806.
[16]	Singh, Y., Garg, M.K., Tandon, N.and Marwaha, R.K. (2013). A study of insulin resistance by HOMA-IR and its cut-off value to identify metabolic syndrome in urban Indian adolescents. J. Clin. Res. Pediatr. Endocrinol .5(4):245-251.
[17]	Ohkawa,H., Ohishi, N.and Yagi, K. (1979). Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal.Biochem.95(2):351-358..
[18]	Sedlak ,J., and Lindsay R.H. (1968). Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman's reagent.Anal.Biochem.25(1):192-205.
[19]	Lowry, O.H. andRosebrough, N.J., Farr,A.L.and Randall,R.J. (1951). Protein measurement with the Folinphenol reagent.J.Biolo. Chem. 193(1):265-275.
[20]	Gong, J., Qian, L., Kong, X, Yang, R., Zhou, L., Sheng, Y., Sun, W., Sun, F., Huang, Y.and Cao, K.(2007).Cardiomyocyte apoptosis in the right auricle of patients with ostiumsecundum atrial septal defect diseases. Life Sci. 80(12):1143-1151.
[21]	Juan, W. S.,Lin, H. W.,Chen, Y. H.,Chen, H. Y.,Hung, Y. C.,Tai, S. H.,Huang, S. Y.,Chen, T. Y.and Lee, E. J.(2012). Optimal Percoll concentration facilitates flow cytometric analysis for annexin V/propidium iodine-stained ischemic brain tissues. Cytometry Part A. 81(5):400-408.
[22]	Sheela, N., Jose, M.A., Sathyamurthy, D.and Kumar, B.N.(2013).Effect of silymarin on streptozotocin-nicotinamide-induced type 2 diabetic nephropathy in rats.Iranian J. Kidney Diseases. 7(2):117-123.
[23]	Shirwaikar, A., Rajendran, K., Dinesh Kumar,C.andBodla, R.(2004).Antidiabeticactivity of aqueous leaf extract of Annonasquamosa in streptozotocin-nicotinamide type 2 diabetic rats. J. Ethnopharma. 91(1):171-175.
[24]	Soto, C., Mena, R., Luna, J., Cerbon, M., Larrieta, E., Vital, P., Uria, E., Sanchez, M., Recoba, R., Barron, H. et al. (2004). Silymarin induces recovery of pancreatic function after alloxan damage in rats. Life sci. 75(18):2167-2180.
[25]	Soto, C.P., Perez, B.L., Favari, L.P., Reyes, J.L.: Prevention of alloxan-induced diabetes mellitus in the rat by silymarin (1998). Comp. Biochem. Physiol. C Pharmacol. Toxicol. Endocrinol. 119(2): 125-129.
[26]	Loguercio, C., Andreone, P., Brisc, C., Brisc, M. C., Bugianesi, E., Chiaramonte, M., Cursaro, C., Danila, M., deSio, I., Floreani, A., Freni, M. A., Grieco, A. and Groppo, M.et al. (2012). Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: a randomized controlled trial. Free Radic..Biol. Med. 52(9):1658-1665.
[27]	Roeters van Lennep, J.E., Westerveld, H.T., Erkelens, D.W.and Van der Wall, E.E.(2002). Risk factors for coronary heart disease: implications of gender. Cardiovasc. Res. 53(3):538-549.
[28]	Miguez, M.P., Anundi, I., Sainz-Pardo, L.A. and Lindros, K.O.(1994).Comparative study of the hepatoprotective effect of silymarin and silybin on isolated rat hepatocytes. Toxicolo. In Vitro.8(4):581-583.
[29]	SabeenaFarvin, K. H., Anandan, R., Kumar, S. H., Shiny, K. S., Sankar, T. V. and Thankappan, T. K.(2004).Effect of squalene on tissue defense system in isoproterenol-induced myocardial infarction in rats. Pharmacol.Res .50(3):231-236.
[30]	Abd El-Aziz, M.A., Othman, A.I., Amer, M.and El-Missiry, M.A.(2001).Potential protective role of angiotensin-converting enzyme inhibitors captopril and enalapril against adriamycin-induced acute cardiac and hepatic toxicity in rats.J. Appl.Toxicol. 21(6):469-473.
[31]	Soto, C., Perez J, Garcia VUria, E., Vadillo, M. and Raya, L.(2010). Effect of silymarin on kidneys of rats suffering from alloxan-induced diabetes mellitus. Phytomedicine. 17(14):1090-1094.
[32]	Turgut, F., Bayrak, O., Catal, F., Bayrak, R., Atmaca, A. F., Koc, A., Akbas, A., Akcay, A. and Unal, D.(2008). Antioxidant and protective effects of silymarin on ischemia and reperfusion injury in the kidney tissues of rats. Int. Urol.Nephrol. 40(2):453-460.
[33]	Wu, D.F., Peng, R.X., Ye, L.P. and Yu, P. (2003). The effects of silymarin on hepatic microsomal and mitochondrial membrane fluidity in mice. Zhongguo. Zhong. Yao.Za.Zhi. 28(9):870-872.
[34]	Rao, P.R. and Viswanath, R.K.(2007). Cardioprotective activity of silymarin in ischemia-reperfusion-induced myocardial infarction in albino rats.Exp.Clin.Cardiol. 12(4):179-187.
[35]	Khurana, S., Hollingsworth, A., Piche, M., Venkataraman, K., Kumar, A., Ross, G. M. and Tai, T. C.(2014). Antiapoptotic actions of methyl gallate on neonatal rat cardiac myocytes exposed to H2O2. Oxid.Med. Cell Longev.2014:657512.
[36]	Mehmeti, I., Lenzen, S. and Lortz, S.(2011). Modulation of Bcl-2-related protein expression in pancreatic beta cells by pro-inflammatory cytokines and its dependence on the antioxidative defense status.Mol. Cell Endocrinol. 332(1-2):88-96.
[37]	Patel, N., Joseph, C., Corcoran, G.B. and Ray, S.D. (2010). Silymarin modulates doxorubicin-induced oxidative stress, Bcl-xL and p53 expression while preventing apoptotic and necrotic cell death in the liver. Toxicol.Appl.Pharmacol. 245(2):143-152.
[38]	Zhu, S. Y., Dong, Y., Tu, J., Zhou, Y., Zhou, X. H. and Xu, B. (2014). Silybummarianum oil attenuates oxidative stress and ameliorates mitochondrial dysfunction in mice treated with D-galactose. Pharmacogn. Mag .10(Suppl 1):S92-99.
[39]	Azad, N.,Iyer, A., Vallyathan, V., Wang, L., Castranova, V., Stehlik, C.. and Rojanasakul, Y. (2010). Role of oxidative/nitrosative stress-mediated Bcl-2 regulation in apoptosis and malignant transformation.Ann. N. Y Acad. Sci. 1203:1-6.